Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group.
about
Improving the outcome for children with cancer: Development of targeted new agents.Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment.Pediatric chronic myeloid leukemia is a unique disease that requires a different approachManagement of chronic myeloid leukemia in childhood.Children's Oncology Group's 2013 blueprint for research: acute myeloid leukemiaTherapeutic approaches to haematological malignancies in adolescents and young adults.Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia.Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.Treatment of chronic phase chronic myeloid leukemia with imatinib.Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience.Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial.Carbamazepine-imatinib interaction in a child with chronic myeloid leukemia.Response to tyrosine kinase inhibitors in chronic myeloid leukemia: experience from a west Asian developing country.Optimal management for pediatric chronic myeloid leukemia.
P2860
Q36238795-5E1CFD9D-D0EF-4032-8662-C358CF9E6D33Q36577661-67B59668-C77A-4AD9-8408-B2BCF6FFF0C9Q37025981-F9649284-0B77-48E7-BE46-7E3C18D4E4D3Q37991223-B2525AE8-E11D-4780-8817-E99DDB94EF35Q38068816-E92B94E1-7AC8-4552-B13B-EACA011D9AA5Q38134399-18221456-3624-4120-B556-56AFA589D0DEQ38813874-178D8E61-095E-41FF-B7B6-CFD8F4C5CE0DQ43841175-C3D538AC-0FD9-4342-BE2B-DCC4358A4D96Q44774546-B80FFF42-AD56-48E9-8A96-69D020999226Q49101349-8D94547E-8D50-4DDA-9859-6453997ACFA2Q52677126-6EA7B51C-DD8F-410D-AEB3-601738B1E336Q54319964-895FD8F1-8B8B-42DD-AD72-6F33475666C8Q54333450-123CF9ED-B7D8-4ADB-BB81-D63D3AD16A7FQ55034870-F754570C-ED26-4554-B2AC-018077577976
P2860
Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Higher dose imatinib for child ...... the Children's Oncology Group.
@en
Higher dose imatinib for child ...... the Children's Oncology Group.
@nl
type
label
Higher dose imatinib for child ...... the Children's Oncology Group.
@en
Higher dose imatinib for child ...... the Children's Oncology Group.
@nl
prefLabel
Higher dose imatinib for child ...... the Children's Oncology Group.
@en
Higher dose imatinib for child ...... the Children's Oncology Group.
@nl
P2093
P2860
P356
P1476
Higher dose imatinib for child ...... the Children's Oncology Group.
@en
P2093
Cecilia H Fu
Charlotte Wood
Franklin O Smith
Helen Chen
Linda D Cooley
Mark L Bernstein
Martin A Champagne
Mary Ellen French
Myron Chang
Robert B Gerbing
P2860
P356
10.1002/PBC.23031
P577
2011-04-04T00:00:00Z